Convergence of tuberculosis and diabetes mellitus: Time to individualise pharmaceutical care

International Journal of Clinical Pharmacy

Volumn 33, Issue 1, 2011, Pages 44-52

  Gnanasan, Shubashini ^a   Ting, Kang Nee ^b   Wong, Kok Thong ^b   Ali, Salmiah Mohd ^c   Muttalif, Abdul Razak ^d   Anderson, Claire ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM MALAYSIA CAMPUS   (Malaysia)

^c UNIVERSITI TEKNOLOGI MARA   (Malaysia)

^d Penang Adventist Hospital   (Malaysia)

Author keywords

Action research; Diabetes mellitus; Individualised care; Malaysia; Pharmaceutical care; Pharmacist; Tuberculosis

Indexed keywords

ACARBOSE; ETHAMBUTOL; GLIBENCLAMIDE; GLICLAZIDE; GLUCOSE; INSULIN; ISONIAZID; METFORMIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIABETES MELLITUS; DIZZINESS; EXTRAPULMONARY TUBERCULOSIS; FEASIBILITY STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEALTH CARE MANAGEMENT; HEALTH SERVICE; HUMAN; INDIVIDUALIZATION; INSULIN DEPENDENT DIABETES MELLITUS; LIVER DISEASE; LUNG TUBERCULOSIS; MALAYSIA; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHARMACEUTICAL CARE; PHARMACIST ATTITUDE; PREVALENCE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PRURITUS; TUBERCULOSIS; VISUAL DISORDER; VOMITING;

ADULT; AGED; COMORBIDITY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG TOXICITY; FEASIBILITY STUDIES; FEMALE; HUMANS; MALAYSIA; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PHARMACEUTICAL SERVICES; PROFESSIONAL ROLE; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 79960065496     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-010-9452-3     Document Type: Article

References (42)

1. Harries DA, Murray MB, Jeon CY, Ottmani SE, Lonnroth K, Barreto ML, et al. Defining the research agenda to reduce the joint burden of disease from Diabetes mellitus and Tuberculosis. Trop Med Int Health. 2010;15:659-63.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2,000 and projections for 2030. Diabetes Care. 2004;27:1047-53. (Pubitemid 38579764)
3. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: A systematic review of 13 Observational Studies. PLoS Medicine. 2008;5:e152. doi:10.1371/journal.pmed.0050152.
4. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: Convergence of two epidemics. Lancet Infect Dis. 2009;9: 737-46.
5. Wang CS, Yang CJ, Chen HC, Chuang SH, Chong IW, Hwang JJ, et al. Impact of type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis. Epidemiol Infect. 2009;137: 203-10.
6. Stevenson CR, Forouhi NG, Roglic G, Williams BG, Lauer JA, Dye C, et al. DM and tuberculosis: The impact of the DM epidemic on tuberculosis incidence. BMC Public Health. 2007;7:2 34.
7. Dooley KE, Tang T, Golub JE, Dorman SE, Cronin W. Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. Am J Trop Med Hyg. 2009;80:634-9.
8. Nissapatorn V, Kuppusamy I, Jamaiah I, Fong MY, Rohela M, Khairul Annuar A. Tuberculosis in diabetes patients: A clinical perspective. Southeast Asian J Trop Med Public Health. 2005;36:213-20.
9. Bashar M, Alcabes P, Rom WN, Condos R. Increased incidence of multi-drug resistant tuberculosis in diabetic patients on the Bellevue Chest Service, 1987 to 1997. Chest. 2001;120:1514-9. (Pubitemid 33078466)
10. Chan JCN, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, et al. Diabetes in Asia: Epidemiology, risk factors, and pathophysiology. JAMA. 2009;301:2129-40.
11. Rampal S, Rampal L, Rahmat R, Md Zain A, Yee GL, Mohamed M, et al. Variation in the prevalence, awareness, and control of diabetes in a multiethnic population: A nationwide population study in Malaysia. Asia Pac J Public Health. 2010;22:194-202.
12. WHO. country health information profile. [Cited 2010, Aug 4]. Available from, http://www.wpro.who.int/NR/rdonlyres/DA2B 128C-C64C-45FA-B1E1- D3FF8590EC71/0/19finalMAApro09. pdf.
13. Odegard PS, Gray SL. Barriers to medication adherence in poorly controlled diabetes mellitus. Diabetes Educ. 2008;34:692-7.
14. Munro SA, Lewin SA, Smith HJ, Engel ME, Fretheim A, Volmink J. Patient adherence to tuberculosis treatment: A systematic review of qualitative research. PLoS Med. 2007;4:1230-45. (Pubitemid 47196226)
15. World Health Organisation. An expanded DOTS framework for effective tuberculosis contro. Int J Tuberc Lung Dis. 2002;6: 378-88.
16. Gnanasan S, Wong KT, Mohd Ali S, Ting KN, Anderson C. Pharmacist-led medication therapy adherence clinic: Exploring views of health care professionals. Int J Pharm Pract. 2010; 18(Suppl 1):S24-5.
17. Townsend A, Hunt K, Wyke S. Managing multiple morbidity in mid-life: A qualitative study of attitudes to drug use. BMJ. 2003;327:837-40.
18. Tulip S, Campbell D. Evaluating pharmaceutical care in hospitals. Hosp Pharm. 2001;8:275-9. (Pubitemid 33115745)
19. Medical Research Coucil. A framework for development and evaluation of RCTs for complex interventions to improve health. London: MRC. 2000.
20. Gnanasan S, Ting KN, Wong KT, Mohd Ali S, Muttalif AR, Anderson C. Medication beliefs and concerns among patients with tuberculosis and diabetes mellitus. 16th international social pharmacy workshop. Pharm Pract (Internet). 2010;8(Suppl 1): 1-136.
21. Gnanasan S, Wong KT, Mohd Ali S, Muttalif AR, Ting KN, Anderson C. Exploring the need for pharmaceutical care (PC) management of tuberculosis and diabetes mellitus (TBDM) in Malaysia. Abstracts of the PCNE 7th Working Conference. Pharm World Sci. 2009;31:503.
22. Meyer J. Qualitative research in health care. Using qualitative methods in health related action research. BMJ. 2000;320: 178-81.
23. Hart E, Bond M. Action research for health and social care: A guide to practice: Buckingham: Open University Press. 1995.
24. Tanna NK. Action Research: A valuable research technique for service delivery development. Pharm World Sci. 2005;27:4-6. (Pubitemid 40362669)
25. Gilbert AL, Roughead EE, Beilby J, Mott K, Barratt JD. Collaborative medication management services: Improving patient care. Med J Aust. 2002;177:189-92. (Pubitemid 35021429)
26. Tanna N, Pitkin J, Anderson C. Development of the specialist menopause pharmacist (SMP) role within a research framework. Pharm World Sci. 2005;27:61-7. (Pubitemid 40362676)
27. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47:533-43. (Pubitemid 20138134)
28. Clark PM, Karagoz T, Apikoglu-Rabus S, Vehbi IF. Effect of pharmacist-led patient education on adherence to tuberculosis treatment. Am J Health Syst Pharm. 2007;64:497-506. (Pubitemid 46339264)
29. Mitrzyk BM. Treatment of extensively drug-resistant tuberculosis and role of the pharmacist. Pharmacotherapy. 2008;28:1243-54.
30. Elliott RA, Ross-Degnan D, Adans AS, Safran DG, Soumerai SB. Strategies for coping in a complex world: Adherence behavior among older adults with chronic illness. J Gen Intern Med. 2007;22:805-10. (Pubitemid 46763986)
31. Struijs JN, Baan CA, Schellevis FG, Westert GP, van de Bos GA. Comorbidity in patients with diabetes mellitus: Impact on medical health care utilization. BMC Health Serv Res. 2006;6:84. doi: 10.1186/1472-6963-6-84. (Pubitemid 44214753)
32. Marra CA, Marra F, Cox VC, Palepu A, Fitzgerald M. Factors influencing quality of life in patients with active tuberculosis. Health Qual Life Outcomes 2004;2. 58 doi:10.1186/1477-7525-2-58. (Pubitemid 40472025)
33. Benson J, Britten N. Patients' decisions about whether or not to take antihypertensive drugs: Qualitative study. BMJ. 2002;325: 873-6. (Pubitemid 35215261)
34. Gordon K, Smith F, Dhillon S. Effective chronic disease management: Patients' perspectives on education-related problems. Patient Educ Couns. 2007;65:407-15. (Pubitemid 46241782)
35. Pound P, Britten N, Morgan M, Yardley L, Pope C, Daker-White G, et al. Resisting medicines: A synthesis of qualitative studies of medicine taking. Soc Sci Med. 2005;61:133-55. (Pubitemid 40545066)
36. Rao PV. Persons with type 2 diabetes and co-morbid active tuberculosis should be treated with insulin. Int J Diabetes Dev Ctries. 1999;19:79-86.
37. Kotokey RK, Bhattaharya D, Das P, Azad A, De A. Study of efficacy of DOTS in pulmonary tuberculosis patients with associated diabetes. Lung India. 2007;24:58-60.
38. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med. 1993;328:1676-85. (Pubitemid 23157351)
39. Chandran M, Chu NV, Edelman SV. Gastrointestinal disturbances in diabetes. Curr Diab Rep. 2003;3:43-8. (Pubitemid 38906764)
40. Javadi MR, Shalviri G, Gholami K, Salamzadeh J, Maghooli G, Mirsaeedi SM. Adverse reactions of anti-tuberculosis drugs in hospitalized patients: Incidence, severity and risk factors. Pharmacoepidemiol Drug Saf. 2007;16:1104-10. (Pubitemid 350020063)
41. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167:1472-7. (Pubitemid 37363354)
42. Piette JD, Heisler M, Wagner TH. Cost-related medication underuse: Do patients with chronic illnesses tell their doctors? Arch Intern Med. 2004;164:1749-55. (Pubitemid 39215643)